Oncology & Cancer

The story of GARP: a potential target for cancer immunotherapy

Colorectal cancer is the third leading cause of cancer-related deaths in both men and women. Despite significant advances in therapies for this particular cancer, the five-year survival rate is 12 percent, according to the ...

Oncology & Cancer

New cancer immunotherapy drugs rapidly reach patients after approval

The majority of patients eligible for cancer immunotherapy drugs known as checkpoint inhibitors received treatment within a few months of FDA approval, according to a new Yale-led study. The finding suggests that cancer immunotherapies ...

Oncology & Cancer

Evaluating quality of life after kidney cancer treatments

Patients with an advanced form of kidney cancer had similar quality of life outcomes taking a drug called cabozantinib as those who received the standard treatment, everolimus, according to a new Northwestern Medicine study. ...

page 3 from 15